智通财经APP讯，科济药业-B(02171)发布公告，舒瑞基奥仑赛注射液(产品编号：CT041，一款靶向Claudin18.2蛋白的自体CAR-T细胞治疗候选产品)在晚期胃癌╱胃食管交界处腺癌(G/GEJA)患者中作为一线治疗后的序贯治疗的长期分析研究结果于美国中部夏令时间2026年5月30日13:30 – 16:30在2026年美国临床肿瘤学会(ASCO)年会上进行壁报展示。更多详情请参见公司官网 https://www.carsgen.com 。
发表在2026ASCO年会上的摘要标题为“舒瑞基奥仑赛注射液作为晚期胃癌一线治疗后序贯治疗的长期随访 —— 一项亚组分析”(Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a subgroup analysis)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.